Global Hemophilia Treatment Market, by Product Type (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Antifibrinolytic Agents, and Desmopressin), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 11,474.3 million in 2018, and is expected to exhibit a CAGR of 5.9%, over the forecast period (2019-2027).
Increasing incidence & prevalence of hemophilia or factor VIII deficiency is expected to drive growth of the hemophilia treatment market over the forecast period. For instance, according to the World Federation of Hemophilia (WFH), around 440,000 people across the globe were suffering from hemophilia, out of which around 173,000 people were diagnosed with hemophilia A or B in 2017. Major players are focused on product launches and approvals owing to the rising demand for hemophilia treatment. For instance, in March 2016, the U.S. Food and Drug Administration approved Kedrion’s Koate Double Viral Inactivation (DVI) Antihemophilic Factor (human) with Mix2Vial, for treatment of factor VIII deficiency. Moreover, in May 2018, Chugai Pharmaceutical Co., Ltd., a subsidiary of Roche Group launched its anticoagulation factor IXa/X humanized biospecific monoclonal antibody/coagulation factor VIII substitute, HEMLIBRA, for routine prophylaxis, to prevent or reduce the frequency of bleeding episodes in patients with congenital factor VIII deficiency (hemophilia A) with factor VIII inhibitors.
Browse 35 Market Data Tables and 21 Figures spread through 188 Pages and in-depth TOC on 'Hemophilia Treatment Market’- global forecast to 2027, by Product Type (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Antifibrinolytic Agents, and Desmopressin), by Disease Indication (Hemophilia A, Hemophilia B, and Hemophilia C), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)'
To know the latest trends and insights prevalent in the Hemophilia Treatment Market, click the link below:
Asia Pacific is expected to offer lucrative growth opportunities for players operating in the hemophilia treatment market owing to the favorable regulatory scenario and guidelines by government authorities, which, in turn, is expected to fuel growth of the market over the forecast period. For instance, according to the World Hemophilia Foundation’s 2015 report of National Tenders for Purchase of Clotting Factor Concentrates, According to the Chinese Ministry of Health report 2012, in China, outpatient hemophilia treatment is covered by health insurance schemes in more than 80% of the cities in China, with reimbursement caps and patient co-pay requirements more than 50%. Moreover, annual reimbursement is usually capped below US$ 16,000. Moreover, several major players in the market are focusing on collaborations with the aim of developing novel therapies for factor VIII deficiency treatment, which is expected to facilitate growth of the market over the forecast period. For instance, in August 2018, RCSI, a Dublin-based international health sciences institution, and Bayer AG entered a research collaboration to develop new treatment options for people with severe hemophilia. Furthermore, in May 2017, Sangamo Therapeutics, Inc., a genomic medicine company, and Pfizer Inc., entered a global collaboration and license agreement for development and commercialization of a gene therapy-based product for treatment of hemophilia A.
Key Takeaways of the Hemophilia Treatment Market: